Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Cross Below Two Hundred Day Moving Average - Time to Sell?

Key Points

• Northwest Biotherapeutics stock has fallen below its 200-day moving average of $0.26, trading as low as $0.23 and last recorded at $0.24.
• The company reported a quarterly earnings loss of ($0.01) per share with a revenue of $0.13 million.
• Northwest Biotherapeutics focuses on developing personalized immune therapies for cancer using a technology called DCVax.

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.26 and traded as low as $0.23. Northwest Biotherapeutics shares last traded at $0.24, with a volume of 1,077,065 shares.

Northwest Biotherapeutics Stock Performance

The stock has a market cap of $386.72 million, a PE ratio of -4.33 and a beta of -1.14. The stock's 50-day moving average is $0.25 and its two-hundred day moving average is $0.26.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The biotechnology company reported ($0.01) earnings per share for the quarter. The company had revenue of $0.13 million for the quarter.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.